Twist Bioscience (TWST) Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TWST shares.
View TWST analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 12-month price targets for Twist Bioscience's stock. Their TWST share price forecasts range from $20.00 to $36.00. On average, they anticipate the company's share price to reach $28.67 in the next twelve months. This suggests a possible upside of 40.9% from the stock's current price.
View analysts price targets for TWST or view top-rated stocks among Wall Street analysts.

Twist Bioscience's stock was trading at $23.81 at the start of the year. Since then, TWST stock has decreased by 14.6% and is now trading at $20.34.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 17th 2023.
View our TWST earnings forecast.

Twist Bioscience Co. (NASDAQ:TWST) released its quarterly earnings results on Friday, August, 4th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.13. The company earned $63.80 million during the quarter, compared to analyst estimates of $60.62 million. Twist Bioscience had a negative trailing twelve-month return on equity of 29.09% and a negative net margin of 88.97%. The firm's quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.08) EPS.

ETFs with the largest weight of Twist Bioscience (NASDAQ:TWST) stock in their portfolio include Subversive Mental Health ETF (SANE), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), Global X Telemedicine & Digital Health ETF (EDOC), ROBO Global Healthcare Technology and Innovation ETF (HTEC), WisdomTree BioRevolution Fund (WDNA), BNY Mellon Innovators ETF (BKIV) and SPDR S&P Biotech ETF (XBI).

Twist Bioscience updated its fourth quarter 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $63.00 million-$64.00 million, compared to the consensus revenue estimate of $62.25 million.

44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

(TWST) raised $75 million in an initial public offering on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Twist Bioscience's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (12.18%), BlackRock Inc. (12.03%), JPMorgan Chase & Co. (8.95%), State Street Corp (8.45%), William Blair Investment Management LLC (6.30%) and Sumitomo Mitsui Trust Holdings Inc. (6.24%). Insiders that own company stock include Dennis Cho, Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends.

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TWST stock can currently be purchased for approximately $20.34.

Twist Bioscience (NASDAQ:TWST) has a market capitalization of $1.17 billion and generates $203.57 million in revenue each year. The company earns $-217,860,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis.

The company employs 989 workers across the globe.

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.twistbioscience.com. The company can be reached via phone at (800) 719-0671 or via email at maeve@argotpartners.com.